TheraPure™ GMP RNase Inhibitor, 40 U/μL

Thermo Scientific TheraPure GMP* RNase Inhibitor is manufactured to ICH Q7 GMP principles and supported by a comprehensive documentation package. It is designed to prevent RNA degradation during development and manufacturing of mRNA therapeutics. As a potent noncompetitive inhibitor of RNases A, B, and C, it allows the newly synthesized RNA of in vitro transcription to remain intact.

Designed for process development and manufacturing
TheraPure GMP RNase inhibitor helps accelerate mRNA vaccine and therapeutics production from preclinical development to commercialization by providing:
• Quality—meet critical product quality needs to help accelerate therapeutic development and manufacturing
• Minimal risk—helps reduce risks in developing therapeutics by utilizing proven products
• Technical partnership—partner with expert product and technical support
• Secure and consistent supply—count on a secure and stable supply of product at a global scale

Comprehensive quality system
TheraPure GMP RNase inhibitor is supported by a extensive quality system and documentation including:
• Manufactured to relevant ICH Q7 GMP guidelines
• Animal-origin free (AOF) manufacturing processes, materials, and facilities
• Validated manufacturing processes and analytical test methods
• Comprehensive impurity profiles
• Verified compendial assays where applicable
• Product stability data
• Tested by analytical methods following ICH Q2 guidelines whenever possible
• Drug master file (DMF)

Enzyme activity
One unit is the amount of protein required to reduce the activity of 5 ng of RNase A by 50%.

For additional TheraPure GMP products or customization, please visit www.thermofisher.com/therapure.

*TheraPure GMP refers to the quality level of the raw, ancillary, or starting materials to be used for further manufacturing. TheraPure GMP products are manufactured in facilities with ISO 9001–certified quality management systems that operate in accordance with relevant good manufacturing practice (GMP) principles, as outlined in ICH Q7 or equivalent guidance documents or standards.